The anti-tumor efficacy of curcumin can be markedly improved by nano-drug self-delivery systems with high drug loading capacity and smart stimulus-triggered drug release in tumor cells. Herein, a type of novel, glutathione (GSH)-responsive, PEGylated prodrug nano-micelles (PPNMs) was prepared by self-assembly of curcumin-s-s-vitamin E/mPEG2k-DSPE mixture. The PPNMs (entrapment efficiency: 96.7%) was acceptably stable in water with a mean particle size of 29.84 nm. Compared with curcumin-loaded mPEG2k-DSPE nano-micelles (CUR-NMs), PPNMs showed a higher drug loading (1.68% vs 27.3%) and remarkably improved the chemical stability of curcumin in phosphate buffer saline (PBS) (pH = 7.4), 10% FBS culture medium, and rat plasma. In vitro release study showed that PPNMs could redox responsively control the release of curcumin from the prodrug. Moreover, PPNMs showed a cytotoxicity in HepG2 cells similar to that of the free curcumin; however, when the HepG2 cells were pretreated with 1 mM GSH, PPNMs displayed a markedly enhanced cytotoxicity and cellular uptake than the free curcumin. After intravenous injection, PPNMs showed an increased half-life in blood circulation (10.6-fold) and bioavailability (107-fold) compared with the free curcumin injection. Altogether, the prodrug nano-micelles represent a promising preparation for sustained and controlled delivery of curcumin with enhanced antitumor activity.
Introduction
Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (13% of all deaths) in 2008. Additionally, worldwide cancer-related deaths are predicted to rise continuously to over 11 million in 2030 (Jemal et al., 2010) . Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and has a high incidence in Asia and Africa (Blum, 2011) . The predisposing factors of HCC has been reported to include chronic hepatitis virus infection, environmental exposure, extensive alcohol intake, transgenic oncogene and other causes of hepatic cirrhosis (El-Serag and Rudolph, 2007) . Usually, HCC patients have poor prognosis because of resistance to chemotherapeutic drugs and limited efficacy of radiotherapy (Iwadou et al., 2010) . Additionally, chemotherapeutics such as paclitaxel, doxorubicin and 5-fluorouracil often cause serious systemic side effects such as cardiotoxicity, neurotoxicity, and hepatotoxicity (Chen et al., 2011; Katona et al., 1998; Mayerhofer et al., 2000) . Thus, safe and effective therapies are urgently required for patients with advanced HCC.
Curcumin (CUR), a natural phenolic antioxidant, exhibits extensive pharmacological actions like anti-inflammatory, antioxidant, and anticancer and can prospectively be developed as an anti-tumor and antioxidant drug (Shen and Ji, 2012) . Recent studies have shown that curcumin could prevent and treat multiple types of cancers, including gastrointestinal, melanoma, leukemia, breast, lung, hematological, head and neck, neurological and sarcoma (Anand et al., 2008; Xu et al., 2018) . However, curcumin is extremely hydrophobic and unstable in PBS (pH = 7.4). Moreover, the rapid metabolization and elimination of curcumin in vivo result in a low curcumin concentration in plasma and tumor tissues (Naksuriya et al., 2014) . Hence, it is imperative to improve the hydrophilcity and stability of curcumin.
Over the past few decades, a number of nanodrug delivery systems such as liposome, micelles and nanoparticles, have been developed to improve the solubility and bioavailability of curcumin Peng et al., 2018; Wang et al., 2018) . However, the low drug loading, potential toxicities of carriers, non-active release and non-targeted drug distribution are the major challenges of the traditional nano-carriers Feng et al., 2015; Hou et al., 2016) . Nano-drug selfdelivery systems have gradually attracted attention due to their unique advantages such as the high and fixed content, the ability to avoid rapid clearance and premature burst release (Huang et al., 2014; Li et al., 2017) . Nano-prodrug designed to self-assemble in water solution is one of the carrier-free systems with no worries of carrier's biocompatibility issues (Duhem et al., 2014) . α-Tocopherol, one of the most abundant and active isomer of the vitamin E (VE) family, is a potent antioxidant and has chemopreventive properties against several cancers. More importantly, curcumin in combination with VE possesses stronger antioxidant and hepatoprotective activities than curcumin alone (Venkatanarayana et al., 2012) . In addition, VE and VE moiety could be used as an inhibitor of P-glycoprotein (P-gp) to overcome multidrug resistance (MDR), thus enhancing the oral bioavailability of aquaphobic drugs (Tuguntaev et al., 2017; Wang et al., 2015) .
In this study, curcumin was conjugated with VE through disulfide bond to form the prodrug, which was then mixed with mPEG2k-DSPE to self-assemble into novel PEGylated prodrug nano-micelles (PPNMs) in aqueous solution through nanoprecipitation method. The stability and drug loading of PPNMs were evaluated in comparison with the free curcumin-loaded mPEG2k-DSPE nano-micelles. Importantly, the redoxresponsive release property, cellular uptake, pharmacokinetic studies and antitumor activity of PPNMs were investigated to evaluate the curcumin delivery by PPNMs, and its antitumor activity. Collectively, this study could provide an experimental basis for further development and application of self-assembly nano drug delivery systems for enhancing bioactivity of hydrophobic and unstable drugs.
Materials and methods

Materials
Curcumin, dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), acetic anhydride and vitamin E were obtained from J&K scientific co., Ltd, (Beijing, China). Dithiodiglycolic acid was bought from Aladdin Industrial Corporation (Shanghai, China) . N-(Carbonylmethoxypolyethyleneglycol 2000)-1, 2-distearoyl-sn-glycero-3-phosphoethanolamine (mPEG2k-DSPE) was purchased from A.V.T. Pharmaceutical Co., Ltd (Shanghai, china). The (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and trypsin were obtained from Beyotime Institute of Biotechnology (Jiangsu, China). All other solvents and reagents used for chemical synthesis and HPLC analysis were obtained from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China).
Synthesis of curcumin-s-s-vitamin E conjugate
Dithiodiglycolic acid (5 mmol) and 3 mL anhydrous acetic anhydride were mixed and stirred for 2 h at 30°C. Thereafter, toluene was added to the reaction solution, and then evaporated to dryness in vacuo under reduced pressure. The same procedure was repeated for three times. The anhydride product was dissolved in the anhydrous dichloromethane (10 mL), to which VE (1 mmol) and a catalytic amount of DMAP were added. The mixture was stirred at room temperature for 1 h. The target compound VE-S-S-COOH was purified through the silica gel column chromatography with a mobile phase containing hexane, ethyl acetate and acetic acid (15/1/1) to obtain a yield of 56.3%.
Next, the VE-S-S-COOH (0.2 mmol), DCC (0.23 mmol) and DMAP (0.25 mmol) were dissolved together in 10 mL anhydrous dichloromethane, followed by stirring in an ice-bath for 2 h under a nitrogen atmosphere. The curcumin (0.4 mmol) was then added. The reaction continued for 24 h at room temperature under a nitrogen atmosphere and continuous stirring. Afterwards, the target compound CSSV was purified via silica gel column chromatography with a mobile phase consisting of petroleum ether, ethyl acetate, and acetic acid (3/1/ 1) to obtain a yield of 31.8%. ESI-MS (Thermo LXQ) and nuclear magnetic resonance spectroscopy (400 MHz, Bruker AV-400) were used to confirm the chemical structure of curcumin-s-s-vitamin E conjugate. Chemical formula C 54 H 72 O 10 S 2 . ESI-MS (m/z): 967.73. Figure  S1 ).
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Preparation of PEGylated prodrug nano-micelles
Self-assembled PEGylated prodrug nano-micelles (PPNMs) were prepared by the nanoprecipitation method as previously reported with slight modifications . Briefly, CSSV and mPEG2k-DSPE, with a weight ratio of (4/1, w/w), were dissolved together in DMSO solvent. The mixture was then added drop-wise into water at room temperature with mechanical stirring (∼600-800 rpm) for 5 min. After that, the DMSO was removed from the nano-formulation via dialysis, and the organic solvent-free prodrug nano-micelles were obtained and stored at 4°C. Non-PEGylated nano-prodrug (CSSV-NPs) and curcumin-loaded mPEG2k-DSPE nano-micelles (CNMs) (curcumin/ mPEG2k-DSPE = 1/49, w/w) were prepared following the similar procedures. Unincorporated CUR or CSSV (precipitate) was removed by centrifuging at 5000 rpm for 5 min.
In vitro and in vivo HPLC analysis of CUR and CSSV
The content of CUR and CSSV conjugate was determined by highperformance liquid chromatography (HPLC) with Shimadzu Scientific instrument equipped with an LC-20AT pump and an SPD-20A UV-Vis detector (Shimadzu, Kyoto, Japan) on a reverse ODS Symmetric-C18 column (150 mm × 4.6 mm, 5 μm). The HPLC was thermostated at 30°C with UV detection at 426 nm (CUR) plus 410 nm (CSSV) and a flow rate of 1 mL/min. Water with 0.1% formic acid and methanol were used as mobile phases A and B, respectively. The gradient elution procedure was as follows: 68% B linearly increased to 70% B from 0.01 min to 8 min, followed by equilibration at 100% B for 17 min, but was changed to 68% B for another 10 min. The sample injection volume was 20 µL. Data were presented as means of triplicate samples.
Characterization of PPNMs and CNMs
TEM and DLS analysis
The particle size distribution and zeta potential of PPNMs and CNMs were carried out using dynamic light scattering (DLS). The measurements were performed in triplicates using Zeta Potential/Particle Size analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA). The morphological properties of the PNPs were examined through transmission electron microscopy (TEM) (JEM-2100, JEOL, Tokyo, Japan) operated at an accelerating voltage of 200 kV. A drop of diluted PPNMs solution (0.6 mg/mL) was put on a copper grid and air-dried with filter paper. The sample was stained with phosphotungstic acid solution (2%, w/v) and subsequently viewed under the TEM.
1 H NMR analysis
The PPNMs dispersed in D 2 O was similarly prepared as described above. In brief, CSSV and mPEG2k-DSPE (4/1, w/w) dissolved in DMSO-d 6 solvent was added to the D 2 O solution in drop-wise manner. Then, PPNMs solution was directly analyzed with 1 H NMR.
2.6. The stability studies 2.6.1. Long time stability
The long-time storage study was studied by measuring the mean diameter of the nano-micelles at different temperatures for two months. Briefly, nano-micelles (1 mg·mL −1 ) were incubated in water solution at 4 and 25°C for two months. Particle size of nano-micelles was measured at predetermined time points (0, 5, 15, 30, 45 and 60 days).
Chemical stability of PPNMs
The drug content stability of PPNMs was carried out in PBS (7.4), the cell culture medium containing 10% fetal bovine serum (FBS) or rat plasma according to the previous reports (Wang et al., 1997) . In brief, 10 µL of the nano-micelles solution (1 mM, CUR equivalent) was added into the 900 µL of PBS (7.4) and fresh rat plasma and incubated at 37°C. Aliquots (100 µL) were taken out at predetermined time (0, 0.5, 1, 2, 4, 8, 12 and 24 h), and subsequently mixed with 300 µL of cold acetonitrile. Then, the suspension was centrifuged at 10,000 rpm and the supernatant was analyzed using HPLC.
Hemolysis test of PPNMs
Briefly, fresh rat blood containing heparin was centrifuged at 3000 rpm for 15 min, then washed with physiological saline for three times to obtain the heparinized rat erythrocytes. The purified erythrocytes were diluted with normal saline to form a 4% erythrocytes suspension (v/v). Different concentrations of PPNMs (2, 0.2 and 0.02 mg•mL −1 ) in normal saline were mixed with 0.5 mL of 4% erythrocytes suspensions. The deionized water and normal saline were used as positive control and negative controls, respectively. The mixtures were incubated at 37 o C for 0.5 h and then were centrifuged at 5000 rpm for 5 min. The absorbance of the supernatants was measured using a microplate plate reader (BioTek, USA) plate reader at 570 nm. The hemolysis degree was calculated according to the following equation: Hemolysis (%) = (Abs sample -Abs negative )/(Abs positive -Abs negative )
x 100%. while Abs sample is the absorbance of the PPNMs, Abs negative is the absorbance of the negative control, and Abs positive is the absorbance of the positive control. All samples were analyzed in triplicate.
In vitro release of PPNMs
In vitro release of PPNMs was performed under Water-bathing Constant Temperature Vibrator (SHZ-88, Jintan Medical Instrument Corporation, China) with shaking (100 rpm) at 37 o C in eight different media: 1 µM, 100 µM, 1 or 10 mM GSH in the phosphate buffer saline (pH = 7.4) containing 0.5% Tween 80. Briefly, an aliquot (0.2 mL, 1 mg•mL −1 ) of PPNMs were transferred into 20 mL release media.
Release media of 1 mL was taken at certain time intervals (0, 0.5, 1, 2, 4, 6, 10, 12, 24 h). The collected samples were mixed with 3 mL of cold acetonitrile. Then, the suspension was centrifuged at 10,000 rpm and the supernatant was analyzed by HPLC. The cumulative release (%) was calculated by the weight ratio of released CUR to total CUR in theory.
Cell viability assay
HepG2 cells in logarithmic growth phase were seeded at 4000 cells/ well in DMEM supplemented with 10% (v/v) fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin in 96-well plates. The preparation was cultured at 37°C with 5% CO 2 under fully humidified conditions. Following 24-h incubation, the cells were treated with 100 µL medium containing each of the respective drug samples (free CUR, PPNMs) or pretreated with 1 mM GSH before adding PPNMs, with each having different concentrations (1, 5, 10, 20, 50, 100 µM). After 72-h incubation, MTT solution (20 µL, 5 mg/mL) was added to each well, and the plates incubated further at 37°C for 4 h. Then, DMSO (100 µL) was used to solubilize the formazan crystals and the optical density measured on microplate reader at 595 nm. The cell viability rate (VR) was calculated according to the equation: VR (%) = A/A 1 × 100%, where A refers to the absorbance of treated group and A 1 refers to the absorbance of untreated control group (the vehicle control group) .
Cell uptake of PPNMs
The cell uptake of PPNMs in HepG2 cells was measured with fluorescence microscope. Briefly, HepG2 cells were seeded in 24-well plates at a density of 1 × 10 6 cells/well and incubated for 24 h. Then, the cells were washed and incubated with free CUR (25 µM) solution or PPNMs (25 µM) pretreated with or without 1 mM GSH for 1 h or 6 h at 37°C. Afterwards, the cells were washed with cold PBS for three times and fixed with 4% formaldehyde for 10 min at room temperature. The prepared covered slips were examined by fluorescence microscope (Labophot-2; Nikon, Melville, NY). For quantitative determination, HepG2 cells were seeded in 6-well plates at a density of 1 × 10 6 cells/well for 24 h. Then, the medium was replaced with free CUR (25 µM) solution or PPNMs (25 µM) pretreated with or without 1 mM GSH for 1 h or 6 h at 37°C. After that, the cells were washed with ice-cold PBS for three times. Subsequently, 300 µL of RIPA lysis buffer was added into well to lyse the cells for 30 min. Samples were centrifuged to remove the cellular debris. An aliquot (20 µL) of each cell lysate was used to determine the cell protein content using BCA Protein Assay Kit. The concentration of CUR in cell lysate was determined by HPLC. The uptake index (UI) was calculated as follow: UI = C/P where C is the concentration of CUR in cell lysis and P is the concentration of protein in cell lysis.
Pharmacokinetic study
Twelve male Sprague-Dawley rats weighing 220 ± 20 g (n = 6 for each group) were maintained in an environmentally controlled room (23°C, 12 h dark light cycle) with free access to standard laboratory food and water for 3 days before experiments. All studies were following the Regulations of Experimental Animal Administration issued by the State Committee of Science and Technology of the People's Republic of China, and they were approved by the Jiangsu University of China. The two group were intravenously administrated with CUR injection (Ethanol/Cremophor EL, v/v, 1/1, diluted 20 times with normal saline) and PPNMs of the equivalent CUR dose (5 mg/kg, n = 6), respectively. At predetermined time points (0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24 h), blood samples (about 400 µL) were collected following injection and centrifuged to obtain the plasma. The plasma samples (each of 100 µL) were taken and added to 300 µL acetonitrile. The suspension was then vortex mixed for 3 min and centrifuged at 10,000 rpm for 10 min. The plasma concentration of prodrugs and native CUR in the supernatant was detected using HPLC analysis.
Statistical analysis
Results were expressed as the mean ± standard deviation (SD). Statistical significance differences between treatment groups in the cell study and pharmacokinetic study were assessed using an unpaired Student's t-test. A p-value of < 0.05 was considered statistically significant.
Results
Synthesis of CSSV
The curcumin-s-s-vitamin E conjugate (CSSV) was designed and H.-Y. Zhang et al. International Journal of Pharmaceutics 555 (2019) 270-279 synthesized by conjugating VE with CUR via disulfide bonds (Schemes S1). For the synthesis of CSSV, VE was initially coupled to dithiodiglycolic acid to obtain VE-S-S-COOH. Then, VE-S-S-COOH was conjugated to CUR to yield CSSV. The chemical structure of curcumin-s-svitamin E conjugate was confirmed using 1 H NMR ( Figure S1 ), 13 C NMR (Fig. 1) , HMBC correlation ( Figure S2 ) and ESI-MS ( Figure S3 ).
Preparation and characterization of PPNMs
In order to prepare the PEGylated nano-prodrug, the mPEG2K-DSPE was selected as PEGylated excipients based on a reported literature (Sun et al., 2018) . The Dynamic light scattering (DLS, Fig. 2A ) analysis illustrated that the number-averaged hydrodynamic diameters of CSSVNPs was 211.63 ± 2.51 nm (PDI = 0.105 ± 0.052), and the Zeta potential was -16.39 ± 1.21 mV. However, the PPNMs showed the particle size of 29.84 ± 0.89 nm (PDI = 0.261 ± 0.06) and Zeta potential of -21.47 ± 1.59 mV. The TEM micrograph (Fig. 2) showed the spherical structure of CSSV-NPs and PPNMs. The marked size difference between the CSSV-NPs and PPNMs was also observed in the TEM micrograph.
The DLCs of free curcumin loaded mPEG2K-DSPE nano-micelles prepared at the ratio of 1/49 (w/w) were only 1.68% (Table 1 ), while that of PPNMs remarkably improved (27.3%). The CSSV prodrugs also led to a significant improvement in the colloidal stability of the drugloaded micelles (Gao et al., 2017) . In this regard, it was hypothesized that there could be some interactions like hydrogen bonds and van der Waals force between the mPEG2K-DSPE and CSSV conjugate (Lu et al., 2015 Fig. 3 . The CSSV and mPEG2K-DSPE showed peaks corresponding to their structures. However, PPNMs in D 2 O majorly showed the PEG and methyl peaks of mPEG2K-DSPE. The absence of CSSV peaks in PPNMs confirmed that CSSV was indeed incorporated into the mPEG2K-DSPE micelles. The extensive broadening of PEG and lipid chain peaks confirmed the interaction between the mPEG2K-DSPE and CSSV conjugate. The interactions between the mPEG2K-DSPE and CSSV conjugate could be the reason for the enhanced drug loading compared with the CNMs.
The stability of PPNMs
The long-time storage stability of the PPNMs was evaluated at 4 o C and 25°C for two months. As a result, the PPNMs displayed non-significant increase of the particle size at 4 o C during the storage time (Table 2) ; however, larger size range was observed at 25°C. This is probably because increase in thermal energy could result in the aggregation of particles as reported (Zhu et al., 2015) . These results showed that PPNMs could be stored at 4 o C for long time.
The drug content stability of PPNMs was carried out in PBS (pH = 7.4), 10% FBS cell culture medium, and rat plasma. At 24 h point, approximately 90.5%, 88.6% and 87.3% of the CSSV conjugate from PPNMs could be detected in PBS (pH = 7.4), 10% FBS culture medium and plasma, respectively (Fig. 4) . Contrariwise, the degradation rate of free CUR was rapid. At the same time, the curcumin content from free CUR solution remained only 0.4%, 0.9% and 29.6% in PBS (pH = 7.4), 10% FBS culture medium and plasma, respectively. In agreement with other reports, free curcumin was rapidly degraded by 90% within 1 h in PBS (pH = 7.4) but was more stable at in 10% FBS culture medium and plasma (Wang et al., 1997) . The stability of PPNMs in PBS (pH = 7.4) containing FBS was evaluated using DLS and the result was shown in the Figure S4 . The result demonstrated that the diameter of PPNMs in PBS (pH = 7.4) containing FBS increased marginally than those in the PBS (pH = 7.4) without FBS. However, the diameter of PPNMs did not significantly change within 24 h in PBS (pH = 7.4) with or without FBS. These results indicated that PPNMs could protect the prodrug from hydrolysis after it was encapsulated in the PEGylated micelles. On the other hand, conjugating with vitamin E could increase the hydrophobicity of curcumin, which improve its stability through water exclusion (Luo et al., 2016) . 
C NMR of curcumin-s-s-vitamin E conjugate and its structure (insert).
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Hemolysis test of PPNMs
Hemolysis test is an important means to evaluate the biocompatibility and biological safety of a formulation or drug. As shown in Fig. 5 , the PPNMs did not cause marked hemolysis (Fig. 5B) . The hemolytic activity of PPNMs ranged from 0.62% to 4.24% when the CSSV conjugate concentration increased from 0.02 to 2 mg/mL (Fig. 5A ). These findings indicated that PPNMs has perfect biocompatibility and safety as its hemolytic activity was lower than 5%.
In vitro release
To verify that GSH was able to cleave the disulfide bond of the CSSV and, consequently release the native curcumin, the in vitro release of PPNMs, upon the addition of 0-10 mM GSH, were investigated at 37°C in PBS (pH = 7.4) containing 0.5% tween 80. It was observed that only 13.85% or 38.49% of curcumin was released from PPNMs for 24 h at 1 μM or 100 μM GSH media, respectively. In contrast, about 82.03% of curcumin was released from PPNMs in 1 mM GSH media within 10 h and 80.2% of curcumin was released in 10 mM GSH within 4 h. The release rate of curcumin from PPNMs in different GSH concentrations was 10 mM > 1 mM GSH > 100 μM GSH > 1 μM GSH (Fig. 6) . The GSH-triggered drug release was due to the disulfide bonds inserted in the prodrugs . The GSH-induced drug release mechanism was provided in Scheme S2. The cleavage of disulfide bonds could be transferred into hydrophilic curcumin-SH, which might accelerate the hydrolysis of the adjoining ester bond and the release of curcumin from PPNMs . In general, the glutathione (GSH) concentration in body fluids and normal extracellular matrices (at the µM scale) is several orders lower than that in the cytoplasm and nucleus of tumor cell (mM) Russo et al., 1986 ). Therefore, 1 and 100 µM concentration of GSH in PBS (pH = 7.4) solution were selected as the release media to evaluate the drug release behavior of PPNMs in blood circulation. Also, 1 and 10 mM concentration of GSH in PBS (pH = 7.4) solution was used to determine the drug release pattern of PPNMs in tumor environment Cao et al., 2015) . The GSH-triggered drug release property might have supported the long circulation of prodrug in plasma and on-demand release of curcumin in tumor environment (Meng et al., 2018) .
In vitro cytotoxicity assay
To evaluate the activation function of GSH for PPNMs, HepG2 cells were pretreated with extra 1 mM GSH. After 72-hours incubation, the cell viability of free CUR, PPNMs with and without 1 mM GSH remarkably inhibited the growth of HepG2 cells in a dose-dependent manner (Fig. 7A) . The PPNMs increased cell viability compared with the free drug at the same concentrations of 20, 50 and 100 μM due to the delayed release of CUR from the prodrug nano-micelle. However, the pretreatment of 1 mM GSH to cells significantly increased the cytotoxicity of PPNMs to HepG2 cells due to enhanced GSH content in cells. The half maximal inhibitory concentration (IC 50 ) was summarized in Table 3 . It was found that the IC 50 of PPNMs was closed to that of free CUR (15.10 μM vs 14.18 μM). But the IC 50 of PPNMs with 1 mM GSH was lower than that of free CUR (9.35 μM vs 14.18 μM). These results indicated that the self-assembled nanoparticles produced through the conjugation of CUR with vitamin E could enhance the cytotoxicity of CUR to cancer cell with higher concentrations of GSH.
Cellular uptake of PPNMs
The cellular uptake of free CUR in DMSO alongside PPNMs with and without GSH were studied using fluorescence microscope (Fig. 8) . At 1 h, the fluorescence intensity of free CUR in HepG2 was stronger than that of PPNMs. However, the fluorescence intensity of free CUR was weaker than PPNMs at 6 h due to the instability of free CUR in cell medium (Fig. 5) as well as its efflux from cells mediated by P-glycoprotein (P-gp). In contrast, the intracellular fluorescence intensity of the PPNMs in HepG2 was gradually increased from 1 h point to 6 h point due to its high stability and slow curcumin release. More importantly, PPNMs pretreated with 1 mM GSH to HepG2 shown stronger intracellular fluorescence than that of PPNMs pretreated without GSH at both points (1 h and 6 h).
Quantitative determination study showed the similar results observed by fluorescence microscope in Fig. 7B . The curcumin content in HepG2 after treatment with free CUR was higher than that treated with PPNMs at 1 h point. However, at 6 h, the curcumin content of free CUR decreased to a level lower than that of PPNMs at 6 h. Meanwhile, the curcumin content of PPNMs increased from 1 h to 6 h and was enhanced after pretreatment with 1 mM GSH to HepG2 cells.
The rapid decrease of intracellular curcumin content and fluorescence intensity on HepG2 cells from 1 h to 6 h was caused by the extreme instability and rapid metabolism of curcumin in culture medium containing 10% serum and cytoplasm (Sun et al., 2013) . The PPNMs self-assembled by curcumin-s-s-vitamin E conjugates and mPEG2k-DSPE were remarkably stable in PBS (7.4) and culture medium containing 10% serum. However, after the PPNMs enter the HepG2 cells though endocytosis, the CSSV escapes the acidic endosomes/lysosomes prior to distribution in the subcellular organelles, and is degraded into curcumin in the cytoplasm of high GSH concentration (Marslin et al., 2016) . The aforementioned reasons is the cause of low intracellular curcumin content and fluorescence intensity of PPNMs than that of the free CUR at 1 h, but higher intracellular curcumin content and fluorescence intensity at 6 h. Contrariwise, the cytotoxicity of PPNMs was enhanced with 1 mM GSH possibly due to the marked curcumin release and vitamin E release as P-glycoprotein (P-gp) inhibitor (Kong et al., 2016) .
Pharmacokinetic profiles of PPNMs
In this study, the native drug plasma concentration (C native ) and prodrug plasma concentration (C prodrug ) were simultaneously determined after prodrug nanomicelles dosing. The plasma molar concentration−time curves of the prodrug and the released CUR coupled with their sum were illustrated in Fig. 9 , and the pharmacokinetic parameters are presented in Table 4 . It was observed that the plasma CUR concentration of free CUR injections could not be detected after 2 h (Fig. 9 ). In comparison, the CUR and prodrug CSSV plasma concentration of PPNMs were continuously detectable during the 24-h Fig. 4 . The drug content stability of free CUR and PPNMs in PBS (pH = 7.4), 10% FBS cell culture medium or rat plasma. H.-Y. Zhang et al. International Journal of Pharmaceutics 555 (2019) 270-279 period. Upon PPNMs administration, C prodrug was initially higher than C native at 0.25 h point, but the C native increased and overtook the C prodrug at 0.5 h because PPNMs was rapidly distributed and the prodrug was slowly converted into native CUR in vivo. Compared to the free CUR injection, the half-life (t 1/2 ), mean retention time (MRT), and the area under the plasma concentration-time curve (AUC 0-24h ) of PPNMs (calculated on C native ) increased by 10.6, 7.3 and 107-fold, respectively. On the other hand, the clearance (CL) of prodrug in PPNMs decreased to 145.52 mL/h/kg, being 72.8 -fold lower than that of free CUR injection. The longer t 1/2 and MRT demonstrated that PPNMs could prolong the retention time in systemic circulation because the prodrug was protected by PEGylated micelles. Consistent with other literature reports, PEGylated micelles could avoid elimination from mononuclear phagocytic system and destruction by plasma proteins and phospholipase (Fei et al., 2017; Zhang et al., 2017) . Long systemic circulation of PPNMs contributed to the improved tumor distribution and therapeutic effects through the well-known enhanced permeability and retention (EPR) effect (Oyewumi et al., 2004) . Meanwhile, PPNMs could enhance the on-demand release of the native drug CUR in tumor microenvironment with high GSH concentration (Estrela et al., 2006) . Therefore, the PPNMs self-assembled via curcumin-s-s-vitamin E conjugates and mPEG2k-DSPE hold great potential in delivering curcumin to tumor tissue as a drug carrier. Values are expressed as mean ± SD (n = 3). *p < 0.01, compared with free CUR injection. 
Conclusion
The curcumin-s-s-vitamin E conjugates and mPEG2k-DSPE could assemble into PEGylated prodrug nano-micelles (PPNMs) through nanoprecipitation method. The PPNMs showed a significantly improved stability and DLC compared to CNMs. Furthermore, PPNMs improved chemical instability of the free CUR in PBS (7.4), 10% FBS culture medium and rat plasma. More importantly, PPNMs exhibited GSH-responsive and controlled release of native CUR from the prodrug. The cytotoxicity of PPNMs on HepG2 was similar to that of the free CUR but it increased dramatically after pretreatment with 1 mM GSH. The cellular uptake of PPNMs by HepG2 was gradually increased with the extension of incubation time and addition of GSH, which exceeded that of the free CUR at 6 h. In addition, the PPNMs exhibited a good biocompatibility with remarkably increased t 1/2 (10.6-fold) and bioavailability (107-fold) than those of the CUR. These results indicated that PPNMs is a promising drug delivery system to enhance the cancer cellular uptakes and bioavailability of curcumin. Fig. 9 . In vivo pharmacokinetics of free CUR injection and PPNMs after intravenous injection in rats (Error bars are mean ± SD, n = 5). Values are expressed as mean ± SD (n = 6). *p < 0.01, compared with free CUR injection.
